Movement Disorders

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke and cerebrovascular disease.

Neurology News Network for the week ending July 8, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 7, 2023.

At 1 year, treatment with the investigational cell therapy was well tolerated with no major safety issues and showed evidence of cell survival and engraftment.

The director of movement disorders at the Banner Sun Health Research Institute talked about how research in essential tremor is revolutionizing the diagnosis and understanding of the movement disorder. [WATCH TIME: 5 minutes]

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, talked about the evolution of treatment for Parkinson disease and the new promising therapies patients may seen over the coming years. [WATCH TIME: 3 minutes]

Reasons behind the CRL were not related to efficacy and do not impact Amneal’s 2023 financial guidance, which did not include IPX203 revenues.

Here's some of what is coming soon to NeurologyLive® this week.

Recent advances in artificial intelligence—particularly conversational AI tools such as ChatGPT—suggest promising potential in addressing the issues of loneliness and social isolation in these patient populations.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis.

Neurology News Network for the week ending July 1, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 30, 2023.

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Amit Bar-Or, MD; Gavin Giovannoni, MBBCh, PhD; Dayna Johnson, PhD, MPH, MSW, MS; John Winkelman, MD, PhD; Laxman Bahroo, DO; Ling Wan-Albert, OTD, OTR/L; Sara Pavitt, MD; and Ali Ezzati, MD. [LISTEN TIME: 28 minutes]

At ATMRD 2023, Lori DePorter, global ambassador for the PMD alliance, talked from the patient experience about the need for improved communication between care teams and support groups in Parkinson disease. [WATCH TIME: 3 minutes]

Following the positive results, uniQure expects to initiate a third cohort in the ongoing trial to further investigate both low and high doses of AMT-130 in combination with perioperative immunosuppression.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

In patients with early Parkinson disease, results showed that UB-312 was generally safe and well-tolerated, which supports the advancement of the vaccine into further clinical development.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 23, 2023.

Over a 12-week period, PTC518 showed a safe and tolerable profile, with significant reductions in mutant huntingtin protein and an overall trend towards lowering of neurofilament light levels.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Headache Society.

The assistant professor of occupational therapy at the New York Institute of Technology talked about educating patients with Parkinson disease about the importance of maintaining social participation for cognitive function at ATMRD 2023. [WATCH TIME: 5 minutes]

The nurse practitioner in the movement disorder division at Georgetown University Hospital discussed differences in available therapies for movement disorders versus multiple sclerosis and using a chronic care management model in Parkinson disease. [WATCH TIME: 5 minutes]

Patients with Parkinson disease who were inpatients had significant impacts on their length of stay, readmissions, and morbidity after hospitalization when administered contraindicated medications.